atl1102 new stem cell mobilization indication, page-35

Layman's guidance on ATL1102:

backstory

*stem cell transplant improves clinical outcomes on chemo patients
*blood cells produced in the bone marrow arise from stem cells
*known as hematopoietic, the stem cells are collected from a patient's blood pre-chemo

*because there are only a small number of stem cells in the blood, a growth agent is needed
*growth agents are known as 'mobilization' agents
*mobilization agents are identified by a protein marker (eg. CD34+)

*granulocyte colony-stimulating factor (G-CSF) is the main agent for mobilization of stem cells
*the market for G-CSF is upwards of US$3b pa
*G-CSF, as a successful pathway to mobilization, is enhanced by Mobozil

*first marketed in 2009, Mobozil's 2010 sales ~ US$100m pa
*sales of Mobozil are forecast to rise to ~ US$350m pa
*yet a clinical need still exists to improve on stem cell release achieved by G-CSF/Mobozil

enter ATL1102

*ATL1102 has been found to block a receptor on cells known as VLA-4
*blocking the VLA-4 aids in stem cell release
*ATL1102 is therefore a mobilization agent

pharmacological action and toxicity of ATL1102

*quick pharmacological action (within a week)
*safe and well tolerated toxicity demonstrated in phase II clinical trials of MS patients
*ATL1102 is therefore considered to be at an advanced stage

does ATL1102 demonstrate clinical superiority to G-CSF

*a version of ATL1102 was used in conjunction with G-CSF on mice
*stem cells released increase by a factor of 13 times the mobilization when using G-CSF alone
*ATL1102 therefore shows great potential for improving mobilization of G-CSF

conclusion

ATL1102 has potential to increase mobilization of stem cells harvested for pre-chemo patients

ATL1102 shows clinical superiority to G-CSF by a factor of 13 times

ATL1102 patent is now pending on the mobilization of stem cells